Japanese Cell Therapy Programs

Jaan Cell Clinic partners exclusively with premier Japanese immunotherapy specialist hospitals and will guide you through every step, ensuring you experience world-class immune cell therapy.

Treatment process

Japan Cell Clinic Immune Cell Therapy Blood Collection

🩸 Step 1: Blood collection (approximately 30 mL)

Approximately 30 mL of peripheral blood is collected from the patient.
It is similar to a regular blood test, and there is no significant pain or burden.
NK cell immune cells are isolated from the collected blood.

🔬 Step 2: Cell Culture
(GMP standard facility, approximately 2 weeks)

Isolated immune cells are activated using high concentrations of IL-2, antibodies, and special techniques.
Strictly managed in a Japanese GMP (Good Manufacturing Practice) certified facility.
During this process, the proportion of NK cells increases to an average of 65% of total lymphocytes (range: 45–85%), although it is typically around 20%.
After two weeks of proliferation and quality verification, patient-specific cells are prepared.

Japan Cell Clinic Immune Cell Therapy Cultured Cell Administration

💉 Step 3: Administration (Cell Injection)

Activated and proliferated immune cells are reinjected into the patient's body.
It is administered via intravenous injection and can be used in conjunction with standard chemotherapy. Immune checkpoint inhibitors, such as Opdivo and Yervoy, have been reported to exhibit synergistic effects when combined with cell therapy, and the attending physician will determine whether to use them in combination based on the patient's condition.
It is expected to have effects such as preventing recurrence, suppressing cancer cells, and strengthening immunity.

📈 Step 4: Monitoring (Post-Treatment Progress Management)

After administration, immune cell activity and patient condition are observed for a certain period of time.
If necessary, it may be combined with adjuvant therapy (e.g., nutritional injections, immune boosting therapy).
For the convenience of patients, aftercare is available through collaboration with both Tokyo and Nagoya clinics.

Introduction to representative treatment programs

NK Cell Therapy

Extract NK cells from patient's blood → activate and culture with high concentration of IL-2 → inject
Average activation rate of 65%, minimum of 3 billion cells
Directly targets and eliminates cancer cells, and prevents recurrence. Can be combined with Opdivo and Yervoy immunotherapies.

iNKT cell cancer immunotherapy

iNKT cells are proliferated and injected to attack cancer cells regardless of the presence or absence of antigens.
Activation of NK and killer T cells through IFN-γ secretion, maintaining long-term therapeutic effects
iNKT cell therapy is exclusively available through our Ministry of Health, Labour and Welfare-licensed partner clinic.

Exosome

Promotes recovery and regeneration of damaged tissue through intercellular signaling
Possesses immune-regulating functions, and is safer and more cost-effective than stem cells.
Exosomes are a next-generation regenerative treatment that can be expected to be highly effective at low cost.

NK cell therapy enhanced concurrent therapy

Nivolumab

Restoring anticancer responses by blocking the PD-1 pathway of T cells

Opzivo, developed based on research on the PD-1 protein discovered by Dr. Tasuku Honjo of Japan (Nobel Prize winner in 2018), is a treatment that blocks the PD-1 pathway of immune cells, preventing cancer cells from evading immune cell attacks and restoring anticancer responses.

Yervoy (Ipilimumab)

Amplify T cell activation by inhibiting CTLA-4

This antibody therapy, discovered by Dr. James P. Allison in the United States, boosts T-cell activation by inhibiting the CTLA-4 protein. Blocking CTLA-4 helps to strengthen the immune response against cancer.

Opdivo (Nivolumab) and Yervoy (Ipilimumab) are immune-boosting drugs developed from research achievements recognized with the **2018 Nobel Prize in Physiology or Medicine (announced by the Nobel Prize Committee)**.[1][2]
These two treatments, when combined with NK, iNKT, and activated T-cell therapy, help enhance the immune response and improve treatment efficacy. Furthermore, immune-enhancing treatment combining NK cells with Opdivo/Yervoy is only available in Nagoya, where physicians can directly manage the treatment, due to the risk of "immune overload."

References and official sources
[1] Nobel Prize in Physiology or Medicine 2018 – Press Release, Nobel Prize official site
https://www.nobelprize.org/prizes/medicine/2018/press-release/

[2] Nobel Prize 2018 – Advanced Information (PD-1 & CTLA-4 research)
https://www.nobelprize.org/prizes/medicine/2018/advanced-information/

[3] GenScript – Nobel Prize for Cancer Immunotherapy (checkpoint inhibitors in practice)
https://www.genscript.com/gene-news/cancer-immunotherapy-nobel-prize.html

Ministry of Health, Labor and Welfare.jpg

01. Official approval from the Japanese Ministry of Health, Labor and Welfare

02. Can be used in conjunction with standard chemotherapy, minimizing side effects.

03. Based on internationally verified clinical data

Safety & Evidence

Frequently Asked Questions

Q: Are there any side effects?

Temporary reactions such as high fever may occur, but they will be safely managed at our partner clinic.

Q: Can I receive cell therapy while undergoing chemotherapy?

Yes, concurrent treatment is possible. We will guide you on the optimal method based on your condition.

Q: Can I receive treatment in Nagoya as well?

Yes, we collaborate not only with Tokyo but also with our partner clinic in Nagoya. The Nagoya clinic is equipped with X-ray and ultrasound diagnostic equipment, allowing us to demonstrate the treatment effects through video.

Japan Cell Clinic

For your safe and comfortable Japanese cell therapy,

We operate a counseling channel.

JCC consultation number:

+82-10-2068-1538